Literature DB >> 8042874

Evaluation of adjuvant therapy after surgery for primary carcinoma of the fallopian tube.

M Klein1, A Rosen, M Lahousen, A Graf, N Vavra, B Pakisch, J Poschauko, A Beck, H Kucera.   

Abstract

OBJECTIVE: To evaluate the impact of postoperative therapy (chemotherapy vs. irradiation) on overall survival.
DESIGN: A nationwide retrospective analysis.
SETTING: Hanusch-Krankenhaus, Department of Gynaecology,
SUBJECTS: 115 patients with histologically proved primary carcinoma of the Fallopian tube: 49 received six treatment cycles of a cis-platinum regimen (group I), 24 patients were treated by full irradiation using 50 Gray minimum (group II). The two groups had a similar distribution of stage I and II; in the more advanced stages chemotherapy was the predominant method of treatment.
RESULTS: The five-year survival rate was 53% for women receiving irradiation as against 27% for those given cis-platinum. If the analysis was restricted to those patients with comparable stage I and stage II lesions, the p-value (0.07) was of borderline significance. There was no advantage in adding abdominal to pelvic irradiation (P = 0.62).
CONCLUSIONS: Stage I and stage II carcinoma is probably better treated postoperatively by radiotherapy than chemotherapy. Chemotherapy may have more therapeutic potential in patients with more advanced lesions.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8042874     DOI: 10.1007/bf02390670

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  12 in total

1.  Treatment of fallopian tube carcinoma with cisplatin, doxorubicin, and cyclophosphamide.

Authors:  M Morris; D M Gershenson; T W Burke; J J Kavanagh; E G Silva; J T Wharton
Journal:  Obstet Gynecol       Date:  1990-12       Impact factor: 7.661

2.  Primary carcinoma of the fallopian tube.

Authors:  C Y HU; M L TAYMOR; A T HERTIG
Journal:  Am J Obstet Gynecol       Date:  1950-01       Impact factor: 8.661

3.  Clinical aspects of fallopian tube carcinoma.

Authors:  M G Dodson; J H Ford; H E Averette
Journal:  Obstet Gynecol       Date:  1970-12       Impact factor: 7.661

4.  The management of primary carcinoma of the fallopian tube. Experience of 40 cases.

Authors:  J W Denham; K A Maclennan
Journal:  Cancer       Date:  1984-01-01       Impact factor: 6.860

5.  [Treatment of primary cancer of the fallopian tube].

Authors:  B Pakisch; J Poschauko; G Stücklschweiger; E Poier; M Lahousen; H Pickel; P Kohek; P Klug; A Hackl
Journal:  Geburtshilfe Frauenheilkd       Date:  1990-08       Impact factor: 2.915

6.  Primary carcinoma of the fallopian tube. A retrospective study of patients reported to the Danish Cancer Registry in a five-year period.

Authors:  P Pfeiffer; H Mogensen; F Amtrup; E Honore
Journal:  Acta Oncol       Date:  1989       Impact factor: 4.089

7.  [Primary carcinoma of the Fallopian tube--a clinical study of 37 cases (author's transl)].

Authors:  V Engeler; E Reinisch; W E Schreiner
Journal:  Geburtshilfe Frauenheilkd       Date:  1981-05       Impact factor: 2.915

8.  Fallopian tube carcinoma.

Authors:  G L Eddy; L J Copeland; D M Gershenson; E N Atkinson; J T Wharton; F N Rutledge
Journal:  Obstet Gynecol       Date:  1984-10       Impact factor: 7.661

9.  Adenocarcinoma of the fallopian tube. Experience with 41 patients.

Authors:  J L Benedet; G W White; R N Fairey; D A Boyes
Journal:  Obstet Gynecol       Date:  1977-12       Impact factor: 7.661

10.  Carcinoma of the fallopian tube. Management and sites of failure.

Authors:  E H McMurray; A J Jacobs; C A Perez; H M Camel; M S Kao; A Galakatos
Journal:  Cancer       Date:  1986-11-01       Impact factor: 6.860

View more
  1 in total

Review 1.  Primary fallopian tube cancer: a review of the literature.

Authors:  A C Hellström
Journal:  Med Oncol       Date:  1998-04       Impact factor: 3.064

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.